

1 Cohort Profile: Zhejiang Environmental and Birth Health 2 Research Alliance (ZEBRA) Maternity Cohort

3 Haitong Zhe Sun ^{1,2,3,1*}, Haiyang Tang ^{1,1}, Qingyi Xiang ¹, Siyuan Xu ¹, Jing Fang ^{1,4}, Haizhen
4 Dai ¹, Rui Shi ¹, Yuxia Pan ¹, Ting Luo ^{1,5}, Hangbiao Jin ⁶, Chenyang Ji ⁷, Yuanchen Chen ⁶,
5 Hengyi Liu ⁸, Meirong Zhao ⁷, Kung Tang ⁹, Yuming Guo ¹⁰, Wei Xu ¹¹ and Xiaoxia Bai ^{1,12*}, for
6 the Zhejiang Environmental and Birth Health Research Alliance (ZEBRA) collaborative group

7
8 ¹ Department of Obstetrics, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou,
9 Zhejiang 310006, PR China

10 ² Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK

11 ³ Department of Earth Sciences, University of Cambridge, Cambridge CB2 3EQ, UK

12 ⁴ Lanxi People's Hospital, Jinhua, Zhejiang 321102, PR China

13 ⁵ Wenling Women's and Children's Hospital, Taizhou, Zhejiang 317500, PR China

14 ⁶ Key Laboratory of Microbial Technology for Industrial Pollution Control of Zhejiang Province, College
15 of Environment, Zhejiang University of Technology, Hangzhou, Zhejiang 310032, PR China

16 ⁷ Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Interdisciplinary
17 Research Academy, Zhejiang Shuren University, Hangzhou, Zhejiang 310006, PR China

18 ⁸ Institute of Reproductive and Child Health / National Health Commission Key Laboratory of
19 Reproductive Health, School of Public Health, Peking University Health Science Centre, Beijing
20 100191, PR China

21 ⁹ Vanke School of Public Health, Tsinghua University, Beijing 100084, PR China

22 ¹⁰ School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004,
23 Australia

24 ¹¹ Maternal and Child Health Division, Health Commission of Zhejiang Province, Hangzhou, Zhejiang
25 310006, PR China

26 ¹² Key Laboratory of Women's Reproductive Health, Hangzhou, Zhejiang 310006, PR China

27
28 ¹HZS and HT contributed equally.

29 *Correspondence to zs347@cam.ac.uk (HZS) and baixiaoxia@zju.edu.cn (XB).

30

31 Abstract

32 The Zhejiang Environmental and Birth Health Research Alliance (ZEBRA) established a maternity
33 cohort to investigate the relationship between perinatal abnormalities and various risk factors among the
34 Chinese maternal population. The primary aim of ZEBRA is to explore the feasibility of early-stage risk
35 prediction and the forecast of adverse perinatal symptoms and gestational outcomes. The cohort is
36 ambidirectional, with a retrospective arm tracking 6,275 pregnant females enrolled between 2013 and
37 2016, and a prospective arm recruiting 112,414 participants since the baseline year of 2017. The
38 current ZEBRA maternity cohort database comprises a diverse range of sociodemographic features,
39 physiological characteristics, medical history, therapeutic interventions, and measurements of
40 environmental exposures. Going forward, the cohort will continue to enrol a wider range of participants
41 and collect an even more extensive array of features. ZEBRA is seeking collaborations with both
42 national and international multi-cohort studies to contribute to the field of epidemiology, and provide
43 valuable evidence-based insights for global maternal and child healthcare.

44

45 **Why was the ZEBRA maternity cohort set up?**

46 Before the advent of modern medicine, childbirth carried an extremely high risk of maternal
47 and perinatal mortality (the period beginning at the 20–28th week of gestation and ending at
48 1–4 weeks after delivery). Fortunately, with advances in prenatal healthcare, the prevalence
49 of maternal and perinatal mortalities has significantly reduced. However, gestational
50 hypertension, postpartum haemorrhage, maternal infection, and other antepartum
51 complications are still unneglectable health risks endangering the pregnant women. Under
52 this circumstance, there is an urgent need to implement pragmatic measures to ensure the
53 prolonged health of women during and after pregnancy.

54 Faced with the challenge of an ageing population in China, the central government has
55 advocated the “three-child policy” since 2021 to optimise the population structure ¹. This
56 policy also stressed the importance of maintaining optimal maternal health. The probability of
57 congenital disabilities, such as Down syndrome, neural tube malformation, and congenital
58 heart disease, has been effectively controlled by popularising the new-generation high-
59 sensitivity prenatal screening tools. These include the “double-index method” to investigate
60 cardiac murmurs and transcutaneous oxygen saturation for the timely detection of congenital
61 heart disease ². However, the high occurrence of preterm births (e.g. ~7.8% in China, ~5.9%
62 in Zhejiang) is still a concern ^{3,4}. Preterm labour can increase the risks of multiple congenital
63 disabilities, including low birth weight ⁵, immature organ development ⁶, cerebral palsy ⁷, and
64 mental retardation ⁸.

65 Recent literature has highlighted the impact of environmental exposures on maternal health,
66 encompassing a range of factors such as air pollutants ⁹, green spaces ¹⁰, and extreme
67 temperatures ¹¹. As a response to these hazards, the Zhejiang Environmental and Birth
68 Health Research Alliance (ZEBRA) was established in 2022 under the leadership of the
69 Health Commission of Zhejiang Province. ZEBRA aims to investigate the associations
70 between endogenous physiological factors, exogenous environmental factors, and maternal
71 health ¹². Zhejiang Province was well-suited to lead this pioneering effort for several reasons.
72 Firstly, it is one of the most socioeconomically developed provinces with low perinatal and
73 neonatal mortality rates, allowing for a shift in research focus from individual-level clinical
74 treatment to population-level risk prevention. Secondly, Zhejiang is a leader in cutting-edge
75 interdisciplinary research with access to resources such as the Alibaba Cloud Intelligence
76 Laboratory and DAMO Academy (Academy for Discovery, Adventure, Momentum and
77 Outlook). The first phase of ZEBRA's research (2022–2026) will focus on screening risk
78 factors and exploring the possibility of early-stage prediction for perinatal abnormalities.

79 Perinatal abnormalities include a range of maternal symptoms such as gestational diabetes
80 mellitus, gestational hypertension, pre-eclampsia ^{13,14}, as well as preterm delivery (including
81 spontaneous and indicated preterm birth) ¹⁵. The pathogenesis of perinatal abnormalities is
82 complex and requires further exploration, making population-based cohort studies critical in
83 safeguarding female health. Such studies can identify risk factors that cause perinatal
84 abnormalities, such as insufficient nutrition intake during pregnancy ¹⁵⁻¹⁷, multiple gestations
85 ^{18,19}, pregnancy interval ²⁰, workload ²¹, antepartum complications ²², psychological stress and
86 depression ^{23,24}, and environmental factors ²⁵⁻²⁷. The discoveries of the cohort study will be of
87 significant public health significance for screening high-risk pregnant women, a major
88 commitment made by ZEBRA upon its establishment.

89 Perinatal health protection necessitates collaborative efforts from both families and society,
90 which is crucial for upholding gender equity. The health of women and children is indicative of
91 a civilised society, promoting ongoing advancements in clinical obstetric medicine and public
92 health research. ZEBRA seeks to address several key scientific inquiries. Firstly, are
93 endogenous physiological characteristics and exogenous maternal environmental exposures
94 correlated with perinatal abnormalities? Secondly, do endogenous and exogenous risk factors
95 alter the impact of each other on the risk of perinatal abnormalities? Thirdly, can detectable
96 longitudinal changes in physiological and biochemical markers of pregnant mothers serve as
97 indicators of potential perinatal abnormalities? Fourthly, is it possible to predict the risks of
98 pregnancy-related complications during the middle or even early stages of pregnancy using
99 routine clinical tests? Additionally, is it feasible to achieve rapid risk prediction with easily
100 accessible features that do not require cumbersome additional antenatal visits (e.g. features

101 that can be collected on a smartphone), even among undereducated populations? During the
102 process of epidemiological analysis, ZEBRA pledges to share periodic findings with the China
103 Cohort Consortium²⁸, as well as cohort studies to improve strategies suitable for Chinese
104 economic development and cultural practices.

105

106 **Who is in the cohort?**

107 ZEBRA has been expanding a comprehensive maternity cohort since 2013, initiated in
108 Zhejiang Province, with a goal to establish collaborations nationwide. Over the past few
109 decades, the rate of hospital births in China has witnessed a significant surge, from 60.7% in
110 1996 to 99.7% in recent years^{29,30}. With a developed healthcare system, abundant public
111 health resources, high popularity of multi-level medical units in towns and townships, and a
112 strong emphasis on the health of the general population, the hospital birth rate in Zhejiang
113 had already surpassed 99% in 2002³¹. This forms the social basis for ensuring maternal and
114 neonatal health in the most comprehensive manner possible in Zhejiang Province.

115 ZEBRA enrolls pregnant women and captures their pregnancy, delivery, and puerperium
116 information, along with their neonates, as cohort participants. All pregnant women who
117 choose to give birth at any hospital, adopting the same medical diagnostic criteria (to ensure
118 homogeneity in information collection and inter-centre comparability), are eligible for inclusion
119 in the ZEBRA Maternity Cohort, provided that they consent to share their relevant personal
120 and non-private medical information. The construction and quality control of the ZEBRA multi-
121 centre cohort is led by Hangzhou, the provincial capital city, in collaboration with other
122 prefecture-level cities (Figure 1). The standardisation of the electronic medical system has
123 propelled the ZEBRA Maternity Cohort into a completely new phase as of 2021. On
124 December 9, 2021, the Zhejiang Health and Health Commission held a press conference on
125 the comprehensive reform of mutual recognition and sharing of medical examination records.
126 We are optimistic that more medical records of pregnant women will become eligible for
127 cohort inclusion in future years, with further cross-province database sharing.

128 Zhejiang Province, located in the Yangtze River Delta region on the east coast of China,
129 spans 105,500 square kilometres (longitude 118°01'–123°10' E, latitude 27°02'–31°11' N).
130 The province lies within the Humid Subtropical Climate Zone, characterized by significant
131 monsoon alternation, moderate annual temperature, four distinct seasons, abundant
132 sunshine, and rainfall. However, environmental problems, particularly air pollution, persist in
133 Zhejiang Province. Despite effective reduction campaigns on several criteria air pollutants
134 (i.e. PM₁₀, sulphur dioxide, nitrogen dioxide, and carbon monoxide) in recent years³², the
135 excess rates of PM_{2.5} and ozone (O₃) remain relatively high, at 6.8% and 4.9%, respectively,
136 with peak O₃ concentrations reaching 60–80 ppb³³. Such high O₃ pollution poses population
137 health hazards³⁴ and warrants future environmental epidemiological studies in Zhejiang
138 Province.

139 The selection of Zhejiang as a priority province for the pioneering study of the large maternity
140 cohort is justified by several reasons. Firstly, clinical treatment and primary care must take
141 precedence over data-driven empirical studies, in keeping with the principle of humanism. In
142 cases of limited resources, hospitals, medical schools, and medical research institutes must
143 prioritise the prevention of maternal and neonatal deaths. While China has achieved
144 significant reductions in maternal mortality rates through years of medical staff efforts,
145 significant heterogeneity persists in the geographical distribution of mortality rates. Regions
146 with low maternal mortality rates are concentrated in the east and southeast of China. In
147 Zhejiang, the maternal and infant mortality rates were controlled within 7/100,000 and 5 ‰,
148 respectively, maintaining the lowest levels in China. However, in southwest China, such as
149 Yunnan, the maternal mortality rate was four times higher than that in Zhejiang Province in
150 2012. Therefore, for areas with high maternal mortality, the focus of medicine is still on the
151 care of pregnant women and newborns. When the mortality rate is reduced to the forefront
152 level of senior sister, research based on data will be carried out.

153 Secondly, Zhejiang's critical role in the economic development of China also justifies its
154 selection. In 2020, Zhejiang's GDP reached 936.7 billion US dollars, accounting for 6.4% of
155 the nation-level total GDP and ranking fourth among all provinces. Zhejiang's economy even

156 surpassed that of the Netherlands (909.1 billion US dollars), which ranks 17th worldwide. This
157 flourishing economy also promotes the popularisation of digital medicine, which provides a
158 solid foundation for epidemiological studies, such as the ZEBRA Maternity Cohort and the
159 Zhejiang Birth Cohort (ZBC).

160 Thirdly, geographical coverage and population representativeness were considered in the
161 selection process. Beijing, Shanghai, and Zhejiang are the provincial regions with the lowest
162 maternal and infant mortality rates in China, with the first two regions being municipalities
163 directly under the Central Government. Beijing and Shanghai have attracted individuals with
164 the highest education and economic status in China, with territorial areas of 16,411 and 6,340
165 square kilometres, respectively, which is far less than that of Zhejiang Province (101,800
166 square kilometres). Hence, Zhejiang Province is the ideal location to carry out digital maternal
167 health public health research based on the current situation in China. The ZEBRA study also
168 promises to share clinical experience and research findings with other regions of the country
169 and even the world through the China Cohort Consortium (CCC), with the radiation driving
170 less-developed regions to achieve geographical health justice.

171

172 **How often have the participants been followed up?**

173 The ZEBRA maternity cohort is an open cohort that aims to recruit all pregnant women in
174 Zhejiang Province and follow them throughout pregnancy until six months after delivery, at
175 which point the follow-up will end if no abnormal health conditions are observed. During the
176 pilot study conducted from 2013 to 2016, 6,275 participants were recruited by manually
177 entering their information into the system due to the lack of a widely used interactive data
178 archiving service in the medical system at that time. However, since 2017, Zhejiang Province
179 has officially implemented systematic data management services. As of 31 December 2022, a
180 total of 118,689 pregnant women have been enrolled in the ZEBRA maternity cohort, with the
181 first antenatal visit recorded as the start and delivery (including miscarriage) as the end
182 (Figure 2). All mid-term prenatal examinations of the same pregnant woman are consolidated
183 and archived. Among them, 63,887 pregnant women underwent a 75 g oral glucose tolerance
184 test (OGTT) at 24–28 weeks of gestation in hospitals implementing the same diagnostic
185 standard as matched in the database. Future plans include continuing to follow up with the
186 women and their newborns in the cohort, optimizing cohort sampling, increasing data
187 acquisition channels, and ensuring the information security of cohort participants. Notably,
188 ZEBRA is a cohort that is registered and tracked based on each pregnant woman's prenatal
189 visits, with no intervention in prenatal examination or treatment or additional financial burden
190 imposed on the pregnant women ³.

191 The postpartum follow-up of the ZEBRA maternal cohort is an important aspect of the study,
192 which continues until six months after delivery. The follow-up mainly includes the following
193 procedures:

- 194 1. Within three days after delivery, the mothers undergo a set of fundamental physical
195 examinations. These may include, but are not limited to, a blood routine test (which is
196 decided independently by the obstetrician based on the condition of the pregnant
197 woman), blood pressure measurement, and cardiac function evaluation. If the pregnant
198 woman has pregnancy complications, targeted blood tests may be conducted.
- 199 2. We recommend that mothers undergo a hospital follow-up in the sixth week after delivery,
200 which includes an assessment of weight recovery, blood pressure, and uterine involution.
201 If the pregnant woman has pregnancy complications, targeted blood tests may be
202 conducted.
- 203 3. We advise the mothers to report any abnormal health conditions within six months after
204 delivery to the hospital by telephone. If the hospital has not received any such report, it
205 will conduct a unified telephone follow-up in the sixth month, including an assessment of
206 the mother's blood pressure, weight, and breastfeeding. If the mother is healthy, the
207 cohort follow-up ends, and the participants exit the cohort. However, if the mother has
208 abnormal conditions or shows any signs of abnormal health, we will add a case-by-case
209 follow-up for further clinical observation according to the situation.

210 The follow-up of neonates in the ZEBRA maternal cohort is conducted until six months after
211 birth, and it mainly includes:

- 212 1. Documentation of birth weight and Apgar score at birth.
- 213 2. Clinical observation of jaundice, respiration, and feeding status within three days of birth.
- 214 3. Evaluation of weight and height development at 42 days after birth, and recording of other
215 health abnormalities.
- 216 4. It is recommended that the mother report any abnormal health conditions of the neonate
217 by telephone within six months after birth. If the hospital where the mother gave birth has
218 not received any report, a unified telephone follow-up will be conducted in the sixth month
219 to gather information.

220

221 **What has been measured?**

222 Upon the inception of ZEBRA, a comprehensive investigation was conducted to gather
223 sociodemographic characteristics, medical and disease history, as well as environmental
224 exposure levels for the retrospective portion of the ambidirectional maternity cohort.

225 The sociodemographic characteristics comprise maternal age at delivery, ethnicity (Han or
226 other minorities), occupation, educational attainment (graduate or above, undergraduate,
227 college education, high school or below), place of residence (urban or rural), medical
228 insurance type (New Rural Cooperative Medical Scheme, Urban Resident Basic Medical
229 Insurance, and Urban Employee Basic Medical Insurance), and history of alcohol
230 consumption and smoking, as summarised in [Table 1](#).

231 The electronic medical record system contains a total of 349 pre-pregnancy disease and
232 medical treatment history items. Among these, 70 items have been identified as having an
233 empirical association with reproductive health with prevalence rates higher than 0.05%
234 (diseases with occurrence rates below 0.05% are defined as rare diseases, excluded for
235 gestation-oriented epidemiological studies). Examples of such items include a history of
236 cervical surgery, hepatitis B liver infection, anaemia, syphilis, intrahepatic cholestasis of
237 pregnancy, and depression, among others. [Table 2](#) provides an overview of the prevalence
238 rates of 20 representative pre-pregnancy diseases and histories of surgeries, and [Table 3](#)
239 includes a list of 22 representative obstetric-relevant diagnostic indicators. These indicators
240 include, but are not limited to, gestational weight gain, gestational day, history of live birth,
241 stillbirth, miscarriage, menarche age, neonate birth weight, 1-minute and 5-minute Apgar
242 scores. Full list of pre-pregnancy and gestational diagnostic items (a total of 54) was detailed
243 in [Supplementary Table 1](#) and [2](#), respectively. For each participant in the cohort, a
244 comprehensive set of 60 physiological and biochemical indices were examined at the
245 parturient period and during the 24–28th gestational week oral glucose tolerance test (OGTT),
246 as detailed in [Supplementary Table 3](#). A summary of 28 particularly important indices is
247 provided in [Table 4](#).

248 The establishment of a high-resolution spatiotemporal database has enabled the tracking of
249 individual-level exposures to criteria air pollutants, such as particulate matters (i.e. PM_{2.5})^{35,36}
250 and ozone^{33,37,38}, as well as green space³⁹, humidity, and extreme temperatures⁴⁰ through
251 geospatial projection based on residential location. In the future, with the full operation of the
252 cloud medicine platform, we propose to collect lifestyle features, such as dietary habits,
253 physical exercise, sleeping patterns, and mental conditions, as well as behavioural changes
254 for climate adaptation, and history of medicine and supplement use through smartphone
255 applications. Wearable devices combining chemical and optical probes, pedometers, and
256 GPS are under development to enable high-resolution time-series tracking of personal air
257 pollution exposure, which is scheduled to begin implementation in 2024. For participants
258 willing to provide further biological samples, exposure levels to heavy metals and organic
259 chemical pollutants will also be determined, for example, in placenta samples. Due to
260 limitations in detection techniques and public reluctance to share genetic information, the
261 ZEBRA cohort does not plan to collect gene-level information from participants at this time.

262

263 **What has it found? Key findings and publications**

264 ZEBRA has played a critical role in addressing research gaps related to endogenous (such as
265 sociodemographic and physiological characteristics) and exogenous (such as medical history
266 and environmental exposure) risk factors associated with maternal, perinatal, childbirth, and
267 neonatal abnormalities among Chinese females. As of now, ZEBRA has published more than
268 20 peer-reviewed research articles, reports, reviews, and news pieces. Previous research
269 conducted by ZEBRA primarily involves microscale laboratory experiments, as well as data-
270 driven macroscale population-based epidemiological studies. For the purposes of this
271 summary, we have selected publications that are of significant clinical or public health
272 importance.

273 **Uterine rupture risk factor identification**

274 We identified 19 cases of uterine rupture among pregnant women who had not previously
275 undergone caesarean section between 1992 and 2017. We collected demographic and
276 sociological characteristics, clinical features, and details on the location and extent of the
277 rupture (i.e. complete or incomplete), as well as pregnancy complications and childbirth risk
278 factors (e.g. prolonged labour, dystocia, induced labour, use of oxytocin, etc.). We found that
279 a history of curettage and multiple pregnancy were associated with complete uterine rupture,
280 which was more likely to occur in the fundus of the uterus and at a smaller gestational age,
281 leading to adverse pregnancy outcomes. Neonates with incomplete uterine rupture had
282 higher Apgar scores and lower perinatal mortality⁴¹. While findings from these rare cases
283 may be used for clinical guidance, the limited sample size restricts generalisation, highlighting
284 the need for more cases from the ZEBRA maternity cohort in the future to support these
285 findings.

286 **Neonatal organic pollutant exposure**

287 Currently, research into the pregnancy exposure characteristics and transplacental
288 metastasis of isoforms of per- and polyfluoroalkyl compounds (PFASs) is limited. Such
289 evidence not only advances our comprehension of the mechanism of transplacental transfer
290 of PFASs, but also provides guidance for controlling the production process associated with
291 particular PFASs to lessen occupational and daily exposure. To enhance our understanding of
292 the transplacental and breastfeeding transfer of PFASs, and provide data that supports
293 neonatal health risk assessment, we gathered mother-child paired maternal serum, cord
294 serum, breast milk, or placenta samples from three Chinese cities - Hangzhou, Wuhan, and
295 Mianyang - to capture geographical variability for the determination of various PFAS species'
296 concentrations. The mean concentration of Σ PFAS in maternal serum followed the order of
297 Mianyang (4.44 ng/mL) < Wuhan (9.88 ng/mL) < Hangzhou (19.72 ng/mL)⁴².
298 Perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), and 6:2 chlorinated
299 polyfluorinated ether sulfonates (6:2 Cl-PFESA) were the most prevalent PFASs found in
300 serum^{43,44}. Linear and branched PFOS and PFOA can be effectively transferred across the
301 placenta, with exposure levels ranked in the order of maternal serum > cord serum > placenta
302^{45,46}. Moreover, we have critically summarised the current knowledge on the inner exposure
303 status and mother-to-infant transfer characteristics of PFASs, drawing on hundreds of studies
304 published from 2000 to date, in order to better comprehend this field^{47,48}.

305 In addition, we collected paired serum and cerebrospinal fluid samples from 49 and 22
306 neonates, respectively, to determine the concentrations of PFASs in these biological samples.
307 Our findings showed positive concentrations of PFASs in the cerebrospinal fluid, leading us to
308 conclude that both PFASs and emerging PFAS substitutes have the ability to penetrate the
309 developing blood-cerebrospinal fluid barrier (BCSFB), thus posing a potential risk to the
310 healthy development of newborns⁴⁹.

311 **Air pollution exposure and preterm birth risks**

312 Air pollution has been identified as a critical risk factor for maternal health hazards such as
313 miscarriage, preterm birth, and stillbirths, as reported in existing literature⁵⁰⁻⁵². In this study,
314 we recruited 6789 pregnant mothers with stratified randomisation from 2013 to 2017 in
315 ZEBRA, with a preterm birth prevalence of 5.5%³. We monitored individual-level exposure to
316 criteria air pollutants and estimated that the risk of preterm birth would increase by 13% (95%

317 confidence interval, CI: 3–25%) and 12% (95% CI: 5–19%) with every 10 $\mu\text{g}/\text{m}^3$ additional
318 exposure to $\text{PM}_{2.5}$ and O_3 , respectively. Additionally, we found that low body mass index
319 (BMI), multiple gravidity times, and gestational hypertension also contributed to the risk of
320 preterm birth occurrence.

321 **Mother-to-child intergenerational transmission**

322 In order to investigate the potential transmission of Hepatitis B Virus (HBV) from mother to
323 infant, we obtained placental tissues from three groups of women: 30 healthy pregnant
324 women who were not infected with HBV ($\text{HBV}^{-/-}$), 30 HBV-positive women who did not infect
325 their neonates ($\text{HBV}^{+/-}$), and 30 HBV-positive women who did infect their neonates ($\text{HBV}^{+/+}$).
326 Additionally, peripheral blood samples were collected from the femoral vein of six $\text{HBV}^{+/+}$ and
327 six $\text{HBV}^{+/-}$ neonates. Serum protein expression profiles of HBV were analysed by proteomics,
328 and the expression of proteins related to intrauterine HBV transmission was further confirmed
329 through immunohistochemistry and PCR techniques in both serum samples and placental
330 tissues. After screening and identifying 35 differential proteins, we found that high expression
331 levels of S100-family proteins and exocytosis mediated by the AnxA2-S100A10 complex were
332 associated with intrauterine HBV transmission through the placenta^{53,54}.

333 The intergenerational effects of maternal antibiotic abuse on mother-child health have been a
334 subject of concern among public health researchers, given the evidence of potential hazards
335 to the healthy growth and development of children. Notably, the damage to gut bacteria is a
336 significant outcome of antibiotic exposure⁵⁵. In light of this, we collected breast milk and
337 faecal samples from 25 mothers who received either cefuroxime (CXM) or CXM-cefoxitin
338 (CFX) combined treatments, with faecal samples also obtained from their infants in 2020. Of
339 the 25 participants, nine received no antibiotic treatment, 13 received CXM treatment, and
340 three received CXM + CFX treatment. At a 6-month postpartum follow-up, we collected faecal
341 samples from five infants whose mothers had undergone antibiotic treatments. We analysed
342 the microbiota in both breast milk and faecal samples to investigate the undesirable effects of
343 antibiotics on the microbiota. Furthermore, we compared the relative abundance of antibiotic
344 resistance genes (ARGs) in the infant gut microbiota to investigate their transfer. While
345 antibiotic treatments had no influence on the microbiota of breast milk, they did disturb the gut
346 microbiota in neonates. The abundance of ARGs in the infant gut microbiota showed a
347 declining trend in the antibiotic-treated groups but significantly increased after 6 months of
348 recovery⁵⁶.

349 **Out-of-balance eating quality during COVID-19 pandemic**

350 A cohort of 3689 pregnant women from 19 provinces or municipalities in China were recruited
351 to participate in an online questionnaire survey from 23 January to 29 February 2020, the
352 period classified as the "emergency phase" of COVID-19 epidemic prevention and control in
353 the country. The survey collected demographic information, food intake frequency, and health-
354 related behavioural data of the participants. The study revealed that the overall diet quality of
355 pregnant women was moderately unbalanced during the aforementioned period. The
356 consumption of vegetables, fruits, livestock or poultry meat, dairy products, and nuts were all
357 decreased. Notably, overeating of cereals and potatoes was a major concern in many regions
358 due to restricted access to food supply caused by the lockdown measures⁵⁷.

359 **Gestational effects from severe diseases**

360 Gestational trophoblastic neoplasia (GTN) is a specific tumour that affects pregnant women,
361 originating from the malignant transformation of trophoblastic cells in placental villi during
362 pregnancy. Chemotherapy has been recognised as an effective method to treat GTN,
363 although concerns have been raised regarding its potential impact on pregnancy outcomes.
364 In order to investigate this potential effect, we recruited 319 pregnant patients diagnosed with
365 low-risk GTN in 2018 from the ZEBRA cohort. The patients were divided into two groups
366 according to the occurrence of severe myelosuppression. We found that the occurrence of
367 severe myelosuppression did not have an impact on the chemotherapy effect of methotrexate
368 or the pregnancy outcomes⁵⁸.

369 Gestational diabetes mellitus (GDM) is a crucial issue that has an impact on pregnancy
370 outcomes and the long-term health of pregnant women. To investigate the feasibility of an
371 early clinical diagnosis of GDM, we recruited all pregnant women diagnosed with GDM from

372 the ZEBRA maternity cohort in 2019 and randomly selected healthy pregnant women with
373 normal glucose tolerance as the control group. We used qRT-PCR to detect the expression
374 level of the gene miR-520h in serum samples, and analysed the association between fasting
375 blood glucose (FBG) level and miR-520h expression. Our results revealed that the expression
376 level of miR-520h was up-regulated in the serum of GDM patients. We concluded that miR-
377 520h could serve as a potential biomarker for the earlier-stage diagnosis of GDM ⁵⁹.

378 ZEBRA has directed attention towards understanding the pathological progression of
379 endometrial carcinoma (EC). To this end, we obtained endometrial samples from 345 ZEBRA
380 participants between 2006 and 2013, consisting of 55 normal endometrium (NE), 27 atypical
381 hyperplasia (AH), and 263 Type-I EC. Immunohistochemical staining was performed to
382 investigate the correlation between the expression of the TWIST1 chromosome and survival,
383 as well as clinicopathological characteristics. Our findings indicate that TWIST1 expression
384 gradually increased from NE to AH, implying that heightened TWIST1 expression is a
385 significant indicator of the progression from hyperplasia to AH and eventually malignant
386 tumour. Furthermore, we observed that high TWIST1 expression in Type-I EC patients
387 suggested an increased invasive ability and a greater risk of distant metastasis of the tumour
388 ⁶⁰.

389 At ZEBRA cohort, maternal serum samples were used to participate in the validation of
390 fluorescent probes for the diagnosis of intrahepatic cholestasis of pregnancy (ICP). This study
391 supported the use of a novel diagnostic tool for effective detection of ICP, and promoted the
392 development of new biochemical markers that can better characterize maternal liver function
393 ⁶¹.

394

395 **What are the main strengths and weaknesses of the study?**

396 There are four major strengths of research conducted on ZEBRA maternity cohort. Firstly, to
397 our best knowledge, the ZEBRA maternity cohort represents the first comprehensive
398 pregnancy and childbirth cohort study in China that incorporates various intrinsic factors such
399 as physiological and biochemical characteristics, complete medical histories, and extrinsic
400 factors like environmental exposure, to minimise the bias in risk estimation caused by solely
401 investigating exogenous risk factors as in previous studies. Secondly, in addition to
402 comprehensively evaluating a range of potential risk factors, ZEBRA aims to explore the
403 interaction effects between endogenous and exogenous factors to identify high-risk pregnant
404 women. Thirdly, with more than 0.1 million pregnant women in the cohort, and close to 300
405 tracked factors for each participant, the vast dataset can be employed to develop risk
406 prediction models for early-stage identification of abnormal perinatal outcomes. Fourthly,
407 since 2022, the popularisation of "Cloud Healthcare" has enabled the amalgamation of
408 hospital diagnostic records and self-reported information from smartphone applications to
409 collect health information in a more comprehensive and reliable manner while ensuring the
410 privacy and security of personal information of the cohort participants.

411 The present stage of the ZEBRA maternity cohort study still has several main limitations.
412 Firstly, during the pilot study conducted during 2013–2017, the estimated relative risk values
413 between preterm birth and maternal exposure to air pollutants were highly uncertain due to
414 the small sample size and the lack of effective adjustment for multi-pollutant cross-
415 confounding effects. The risk estimations will be updated in subsequent comprehensive
416 epidemiological studies involving a wider cohort (i.e. from ~6000 to over 0.1 million
417 participants). Secondly, while the current data structure used for analysis categorises
418 populations based on physiological and biochemical indicators and medical history, genetic
419 factors are theoretically the primary method for distinguishing endogenous differences.
420 However, due to ethical requirements, national-level genetic research control, limitations in
421 efficient detection technology, and lower willingness of pregnant women to share genetic
422 information, genetic-level cohort studies are not scheduled to commence before 2025. Lastly,
423 the current ZEBRA cohort study considers relatively few variables related to behavioural
424 characteristics, which are theoretically only obtainable through self-report by participants and
425 thus often have lower credibility. The "Cloud Healthcare" platform is anticipated to enhance
426 the client-based questionnaire survey through artificial intelligence-driven optimisation in the

427 next two years: improvements in the frequency and capacity of data collection, and the
428 implementation of double verification are among the goals for achieving more reliable self-
429 reported indicators by 2025.

430 ZEBRA has pledged to provide evidence-based research conclusions on maternal health for
431 the Chinese population, considering that the majority of high-quality cohort studies have been
432 established in Western countries. ZEBRA aims to set an example in the standardised
433 management of electronic medical records for mother-child pairs at a provincial and national
434 level. Optimised models for screening risk prediction and identification of risk factors using
435 data mining techniques can be promptly applied to newly admitted pregnant women. This
436 approach will improve maternal health risk assessment and update dynamically with the
437 inclusion of cohort participants. Moreover, ZEBRA will take on the responsibility of
438 disseminating maternal health research to the general public, hoping to reduce risks as early
439 as possible.

440 At present, numerous factors are affecting birth rates among young people. However,
441 gynaecologists, physicians, nurses, and medical students are still dedicated to providing the
442 most professional and comprehensive life and healthcare services for women who wish to
443 give birth. The medical and research community is committed to leaving no one behind. By
444 establishing ZEBRA, Zhejiang aims to contribute to the achievement of the "Healthy China
445 2030" vision and the United Nations' Sustainable Development Goals, including SDG3 in
446 maternal and child health, by publishing high-quality research reports and providing
447 epidemiological evidence for global maternal and child healthcare.

448

449 **Can I get hold of the data? Where can I find out more?**

450 ZEBRA is a valuable resource for the research community, offering a wide range and depth of
451 clinical diagnostic information and individual-level tracking of environmental exposure (e.g.
452 PM_{2.5}, O₃, green space and abnormal temperature). While the study database is not publicly
453 available, ZEBRA warmly welcomes potential collaborations, and such requests are
454 considered on a case-by-case basis. Researchers seeking access to the dataset are required
455 to obtain approval from the designated ZEBRA research proposal review committee,
456 comprising the School of Medicine at Zhejiang University and the Maternal and Child Health
457 Division of the Health Commission of Zhejiang Province. International researchers seeking
458 additional information regarding collaboration and data access are encouraged to contact the
459 corresponding authors, Dr. Xiaoxia Bai (baixiaoxia@zju.edu.cn) and Dr. Haitong Z. Sun
460 (zs347@cam.ac.uk), and to specify their requests.

461

462 **Cohort profile in a nutshell**

463 **Zhejiang Environmental and Birth Health Research Alliance (ZEBRA) maternity cohort**

- 464 - The ZEBRA maternity cohort was formulated to examine the links between several
465 categories of perinatal complications and various risk factors in the Chinese maternal
466 population. A paralleled aim is to determine the feasibility of screening and forecasting
467 potential risks during the early stages of pregnancy.
- 468 - The ZEBRA maternity cohort is a unique and comprehensive cohort that operates on an
469 ambidirectional basis. The retrospective arm of the cohort tracks 6,275 pregnant females
470 who were enrolled between 2013 and 2016.
- 471 - The prospective arm has already recruited 112,414 participants since the baseline year of
472 2017. Going forward, the cohort will continue to enrol a wider range of participants and
473 collect an even more extensive array of features.
- 474 - The dataset of the ZEBRA maternity cohort encompasses a diverse array of
475 sociodemographic features, physiological characteristics, medical history, therapeutic
476 interventions, and measurements of environmental exposures.

477 - ZEBRA seeks to establish collaborations with both national and international multi-cohort
478 studies, with the ultimate goal of contributing to the field of epidemiology and providing
479 valuable evidence-based insights for global maternal and child healthcare.

480

481 **Ethics approval**

482 The study obtained written informed consent from all participants, and the research involves
483 the use of de-identified personal information for scientific purposes. The ZEBRA cohort study
484 is approved by the ethics committee of the Women's Hospital, School of Medicine, Zhejiang
485 University (IRB-20220189-R).

486

487 **Funding**

488 The research has received funding from various sources, including the Zhejiang Province
489 Health Innovative Talent Project (A0466), the International Cooperation Seed Program of
490 Women's Hospital, Zhejiang University (GH2022B008-01), the Australian Research Council
491 (DP210102076), the Australian National Health and Medical Research Council
492 (APP2000581), the UK Research and Innovation (UKRI) Centre for Application of Artificial
493 Intelligence to the Study of Environmental Risks (AI4ER, EP/S022961/1), and the US-China
494 Fulbright Program.

495


496 **Acknowledgments**

497 The authors wish to extend their appreciation to several entities for their contributions in the
498 establishment of ZEBRA. Special appreciations to Professor Weiguo Lu, the chief director of
499 the Key Laboratory of Women's Reproductive Health, located in Hangzhou, Zhejiang
500 Province. Specifically, (1) the Department of Maternal Healthcare at Women's Hospital,
501 School of Medicine, Zhejiang University, and (2) the Maternal and Child Health Division at the
502 Health Commission of Zhejiang Province, for providing comprehensive supports. In addition,
503 (3) the TAP (Tracking Air Pollution in China) team at Tsinghua University, (4) the Institute of
504 Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive
505 Health, and the Department of Epidemiology and Biostatistics at the School of Public Health,
506 Peking University Health Science Centre, (5) the School of Atmospheric Sciences at Nanjing
507 University, (6) the Vanke School of Public Health at Tsinghua University, and (7) the School
508 of Public Health and Preventive Medicine at Monash University (Australia) are also
509 acknowledged for their technical assistance. Finally, the authors express gratitude to all
510 ZEBRA cohort participants, as well as the coordinators, administrative and technical staff, and
511 participant interviewers who have made valuable contributions to the cohort study.

512

513 **Figures and Tables**

514




515

516 **Figure 1.** Location of Zhejiang Province and administrative map of prefecture-level cities.

517

518



519

520

521

522

523

Figure 2. Flow diagram of pilot study, baseline recruitment, and follow-up for the Zhejiang Environmental and Birth health Research Alliance (ZEBRA) maternity cohort study.

524

525 **Table 1. Statistics of sociodemographic features of ZEBRA maternity cohort**
526 **participants, 2013–2021.**

Feature	Mean (SD) or Count (%)
Maternal Age at Delivery	30.9 (4.3)
Height (metre)	1.6 (0.1)
Pre-pregnancy BMI	26.4 (3.1)
Ethnicity (Han)	116,671 (98.3%)
Occupation	
Office staff	94,494 (79.6%)
Worker	13,929 (11.7%)
Professional and specialist	2,879 (2.4%)
Farmer	1,045 (0.9%)
Medical staff	364 (0.3%)
Student	157 (0.1%)
Others	5,820 (4.9%)
Education Attainment	
High school or below	19,109 (16.1%)
College education	23,263 (19.6%)
Undergraduate	60,175 (50.7%)
Graduate or above	16,142 (13.6%)
Type of Residence	
Urban	89,227 (75.2%)
Rural	29,462 (24.8%)
Type of Medical Insurance ^a	
NCMS	8,730 (7.4%)
URBMI	7,450 (6.3%)
UEBMI	102,509 (86.4%)
Alcohol and Smoking History	112 (0.1%)

527

528

529

530

^a Medical insurance include three types: New Rural Cooperative Medical Scheme (NCMS) for rural residents, Urban Resident Basic Medical Insurance (URBMI) for non-employed urban residents, and Urban Employee Basic Medical Insurance (UEBMI) for employees.

531

532 **Table 2. Cases and prevalence rates of 20 representative pre-pregnancy diseases and**
533 **histories of surgeries.** Items are listed in descending sequence of prevalence.

Diseases or surgeries	Cases (Prevalence, %)
Anaemia	20,084 (16.9%)
Assisted reproduction	8,194 (6.9%)
Uterine leiomyomas	7,393 (6.2%)
Carrier of hepatitis B virus	6,645 (5.6%)
History of hepatitis B infection	5,129 (4.3%)
Liver abnormality	2,070 (1.7%)
Cervical incompetence	1,413 (1.2%)
Hematopathy	1,142 (1.0%)
History of cervical surgery	968 (0.8%)
Thrombocytopenia	690 (0.6%)
Cardiac arrhythmia	538 (0.5%)
Pelvic inflammation	466 (0.4%)
History of syphilis	434 (0.4%)
Cervical polyps	428 (0.4%)
Congenital uterine malformation	351 (0.3%)
History of ICP	313 (0.3%)
Cervical conisation (LEEP)	303 (0.3%)
History of hypertension	277 (0.2%)
Non-gestational diabetes mellitus	242 (0.2%)
Depression	180 (0.2%)

534

535

536

537 **Table 3. Statistics of obstetric-relevant diagnostic indicators.**

Obstetric-relevant indicators	Mean (SD) or Count (%)
Gravidity	2.1 (1.2)
Parity	1.5 (0.6)
Abortion(s) or miscarriage(s)	
0	69,065 (58.2%)
1 to 2	44,282 (37.3%)
3 to 5	5,173 (4.4%)
above 5	169 (0.1%)
Live birth(s)	
0	66,803 (56.3%)
1	48,994 (41.3%)
2	2,707 (2.3%)
3 or above	186 (0.2%)
Spontaneous singleton delivery	62,818 (52.9%)
Caesarean singleton delivery	51,506 (43.4%)
Stillbirth	1,605 (1.4%)
Gestational days	271 (18)
Preterm birth	12,386 (10.4%)
Singleton preterm birth	11,385 (9.6%)
Twins or multiples	4,926 (4.2%)
Spontaneous preterm birth	6,738 (5.7%)
Singleton spontaneous preterm birth	5,332 (4.5%)
Singleton medical indicated preterm birth	6,053 (5.1%)
Menarche age (years)	13.9 (1.4)
Gestational weight gain (kg)	13.5 (6.0)
Gestational diabetes mellitus	22,393 (18.9%)
Gestational hypertension	2,465 (2.1%)
Pre-eclampsia	6,553 (5.5%)
Severe pre-eclampsia	4,342 (3.7%)
Birth weight, singleton (g)	3,195 (580)
Low birth weight infants, singleton	8,365 (7.0%)
Apgar score, singleton, 1 min	9.7 (1.3)
Apgar score, singleton, 5 min	9.9 (0.5)

538

539

540

541 **Table 4. Representative biochemical indices at parturient period and oral glucose**
542 **tolerance test (OGTT) in second trimester, 24–28th gestational week.**

Biochemical indices	Ref. range	Parturient period	Second trimester
Fasting plasma glucose (mmol/L)	≤5.1		4.9 (1.2)
OGTT 1h plasma glucose (mmol/L)	≤10.0		7.5 (2.1)
OGTT 2h plasma glucose (mmol/L)	≤8.5		7.3 (1.6)
White blood cell count (×10 ⁹ /L)	3.5–9.5	10.7 (3.4)	9.6 (2.2)
Haemoglobin (g/L)	115–150	115.1 (13.8)	114.7 (8.9)
Platelet (×10 ⁹ /L)	125–350	187.0 (49.1)	209.9 (49.2)
Serum protein, total (g/L)	65–85	59.3 (6.1)	64.1 (3.6)
Albumin (g/L)	40–55	33.1 (3.4)	36.4 (2.2)
Alanine aminotransferase (U/L)	7–40	15.2 (24.7)	17.7 (17.4)
Aspartate aminotransferase (U/L)	13–35	21.7 (18.3)	18.7 (11.1)
Bile acids, total (μmol/L)	≤13	4.5 (6.7)	2.3 (3.0)
Lactate dehydrogenase (U/L)	120–250	208.6 (66.7)	157.8 (29.9)
Creatine Kinase (U/L)	40–200	124.8 (167.1)	38.4 (21.2)
Creatinine (μmol/L)	41–73	52.6 (11.4)	51.5 (10.6)
Urea nitrogen (mmol/L)	2.6–7.5	3.1 (1.0)	2.8 (0.7)
Triglycerides (mmol/L)	0.6–1.7	3.2 (1.6)	2.4 (0.9)
Hypersensitive C-reactive protein (mg/L)	≤5.0	17.7 (24.7)	5.2 (6.5)
Prealbumin (g/L)	180–350	203.4 (40.9)	221.6 (30.2)
Transferrin (μmol/L)	2.00–3.60	3.62 (0.69)	3.59 (0.70)
Glycosylated albumin (%)	10.8–17.1	11.6 (1.3)	12.1 (0.9)
Plasma glucose (mmol/L)	≤5.1	0.27 (1.49)	1.46 (2.91)
Prothrombin time (sec)	11.8–13.9	12.6 (0.7)	12.6 (0.5)
International normalised ratio	0.89–1.90	0.98 (0.07)	0.98 (0.05)
Partial thromboplastin time, activated (sec)	29.7–41.8	33.2 (3.0)	31.8 (2.3)
Thrombin time (sec)	15.0–18.0	15.1 (1.0)	14.9 (0.7)
Fibrinogen (g/L)	1.9–3.8	4.6 (0.8)	4.3 (0.7)
Proteinuria			
- (Negative)	-	113,724 (95.8%)	63,600 (99.6%)
+	-	3,328 (2.8%)	206 (0.3%)
++	-	1,226 (1.0%)	51 (0.1%)
+++	-	411 (0.3%)	30 (<0.1%)
Protein excretion, 24-hr (g)	<0.15	1.10 (2.30)	0.10 (0.10)

543

544

545 **References**

546

- 547 1. Tatum M. China's three-child policy. *Lancet* 2021; **397**(10291): 2238.
- 548 2. Wang D, Zhang Y, Jiang Y, et al. Shanghai Preconception Cohort (SPCC) for the association of
549 periconceptional parental key nutritional factors with health outcomes of children with congenital
550 heart disease: a cohort profile. *BMJ open* 2019; **9**(11): e031076.
- 551 3. Sun Z, Yang L, Bai X, et al. Maternal ambient air pollution exposure with spatial-temporal variations
552 and preterm birth risk assessment during 2013-2017 in Zhejiang Province, China. *Environ Int* 2019;
553 **133**(Pt B): 105242.
- 554 4. Qiao J, Wang Y, Li X, et al. A Lancet Commission on 70 years of women's reproductive, maternal,
555 newborn, child, and adolescent health in China. *The Lancet* 2021; **397**(10293): 2497-536.
- 556 5. Goldenberg RL, Culhane JF. Low birth weight in the United States. *Am J Clin Nutr* 2007; **85**(2):
557 584S-90S.
- 558 6. Steer P. The epidemiology of preterm labour. *BJOG* 2005; **112**(Suppl 1): 1-3.
- 559 7. Mallard C, Davidson JO, Tan S, et al. Astrocytes and microglia in acute cerebral injury underlying
560 cerebral palsy associated with preterm birth. *Pediatr Res* 2014; **75**(1-2): 234-40.
- 561 8. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. *N*
562 *Engl J Med* 2008; **359**(3): 262-73.
- 563 9. Bekkar B, Pacheco S, Basu R, DeNicola N. Association of Air Pollution and Heat Exposure With
564 Preterm Birth, Low Birth Weight, and Stillbirth in the US: A Systematic Review. *JAMA Netw Open*
565 2020; **3**(6): e208243.
- 566 10. Zhang L, Shi S, Wu S, et al. Effects of greenness on preterm birth: A national longitudinal study of
567 3.7 million singleton births. *The Innovation* 2022; **3**(3): 100241.
- 568 11. Ren M, Wang Q, Zhao W, et al. Effects of extreme temperature on the risk of preterm birth in China:
569 A population-based multi-center cohort study. *Lancet Reg Health West Pac* 2022; **24**: 100496.
- 570 12. Sun HZ, Xiang Q, Xu S, et al. China's unwavering determination in protecting pregnancy and
571 perinatal health. *The Innovation* 2022; **3**(6): 100336.
- 572 13. Davenport MH, Ruchat SM, Poitras VJ, et al. Prenatal exercise for the prevention of gestational
573 diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis.
574 *Br J Sports Med* 2018; **52**(21): 1367-75.
- 575 14. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth
576 restriction, related or independent conditions? *Am J Obstet Gynecol* 2006; **194**(4): 921-31.
- 577 15. Hendler I, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: association between
578 maternal body mass index and spontaneous and indicated preterm birth. *Am J Obstet Gynecol*
579 2005; **192**(3): 882-6.
- 580 16. Tamura T, Goldenberg RL, Freeberg LE, Cliver SP, Cutter GR, Hoffman HJ. Maternal serum folate
581 and zinc concentrations and their relationships to pregnancy outcome. *Am J Clin Nutr* 1992; **56**(2):
582 365-70.
- 583 17. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. *Am J Clin Nutr*
584 2005; **81**(5): 1218-22.
- 585 18. Fuchs F, Senat MV. Multiple gestations and preterm birth. *Semin Fetal Neonatal Med* 2016; **21**(2):
586 113-20.
- 587 19. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. *BJOG* 2006;
588 **113**(Suppl 3): 17-42.
- 589 20. Smith GC, Pell JP, Dobbie R. Interpregnancy interval and risk of preterm birth and neonatal death:
590 retrospective cohort study. *BMJ* 2003; **327**(7410): 313.
- 591 21. Saurel-Cubizolles MJ, Zeitlin J, Lelong N, et al. Employment, working conditions, and preterm birth:
592 results from the Europop case-control survey. *J Epidemiol Community Health* 2004; **58**(5): 395-401.
- 593 22. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth.
594 *Lancet* 2008; **371**(9606): 75-84.
- 595 23. Hoffman S, Hatch MC. Stress, social support and pregnancy outcome: a reassessment based on
596 recent research. *Paediatr Perinat Epidemiol* 1996; **10**(4): 380-405.
- 597 24. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review
598 of the literature and preliminary findings. *Epidemiol Rev* 1995; **17**(1): 165-71.
- 599 25. Shah PS, Balkhair T, Knowledge Synthesis Group on Determinants of Preterm LBWb. Air pollution

- 600 and birth outcomes: a systematic review. *Environ Int* 2011; **37**(2): 498-516.
- 601 26. Akaraci S, Feng X, Suesse T, Jalaludin B, Astell-Burt T. A Systematic Review and Meta-Analysis of
602 Associations between Green and Blue Spaces and Birth Outcomes. *Int J Environ Res Public Health*
603 2020; **17**(8): 2949.
- 604 27. Chersich MF, Pham MD, Areal A, et al. Associations between high temperatures in pregnancy and
605 risk of preterm birth, low birth weight, and stillbirths: systematic review and meta-analysis. *BMJ*
606 2020; **371**: m3811.
- 607 28. Sun Y, Pei Z, Zhao H, et al. Data Resource Profile: China Cohort Consortium (CCC). *Int J*
608 *Epidemiol* 2020; **49**(5): 1436-m.
- 609 29. National Health Commission of the People's Republic of China. Report on the development of
610 maternal and child health in China. Beijing: Department of Maternal and Child Health, 2019.
- 611 30. Zhang Y, Zhou YB, Li HT, et al. Secular trends of institutional delivery rate in China from 1996 to
612 2015. *Chinese Medical Journal* 2017; **97**(17): 1337-42.
- 613 31. National Bureau of Statistics of China. Development of children health career in Zhejiang. Zhejiang
614 Province: Zhejiang Provincial Bureau of Statistics, 2003.
- 615 32. Ma X, Huang J, Zhao T, et al. Rapid increase in summer surface ozone over the North China Plain
616 during 2013–2019: a side effect of particulate matter reduction control? *Atmos Chem Phys* 2021;
617 **21**(1): 1-16.
- 618 33. Sun H, Shin YM, Xia M, et al. Spatial Resolved Surface Ozone with Urban and Rural Differentiation
619 during 1990-2019: A Space-Time Bayesian Neural Network Downscaler. *Environ Sci Technol* 2022;
620 **56**(11): 7337-49.
- 621 34. Sun HZ, Yu P, Lan C, et al. Cohort-based long-term ozone exposure-associated mortality risks with
622 adjusted metrics: A systematic review and meta-analysis. *The Innovation* 2022; **3**(3): 100246.
- 623 35. Geng G, Xiao Q, Liu S, et al. Tracking Air Pollution in China: Near Real-Time PM_{2.5} Retrievals from
624 Multiple Data Sources. *Environ Sci Technol* 2021; **55**(17): 12106–15.
- 625 36. Wei J, Li ZQ, Lyapustin A, et al. Reconstructing 1-km-resolution high-quality PM_{2.5} data records
626 from 2000 to 2018 in China: spatiotemporal variations and policy implications. *Remote Sens*
627 *Environ* 2021; **252**: 112136.
- 628 37. Xue T, Zheng Y, Geng G, et al. Estimating Spatiotemporal Variation in Ambient Ozone Exposure
629 during 2013-2017 Using a Data-Fusion Model. *Environ Sci Technol* 2020; **54**(23): 14877-88.
- 630 38. Sun Z, Archibald AT. Multi-stage ensemble-learning-based model fusion for surface ozone
631 simulations: A focus on CMIP6 models. *Environ Sci Ecotechnol* 2021; **8**: 100124.
- 632 39. Huete A, Didan K, Miura T, Rodriguez EP, Gao X, Ferreira LG. Overview of the radiometric and
633 biophysical performance of the MODIS vegetation indices. *Remote Sens Environ* 2002; **83**(1-2):
634 195-213.
- 635 40. Hersbach H, Bell B, Berrisford P, et al. The ERA5 global reanalysis. *QJR Meteorol Soc* 2020;
636 **146**(730): 1999-2049.
- 637 41. Zhao P, Su C, Wang C, Xu J, Bai X. Clinical characteristics of uterine rupture without previous
638 Cesarean section: A 25-year retrospective study. *J Obstet Gynaecol Res* 2021; **47**(6): 2093-8.
- 639 42. Liu Y, Liu K, Zheng P, et al. Prenatal exposure and transplacental transfer of perfluoroalkyl
640 substance isomers in participants from the upper and lower reaches of the Yangtze River. *Environ*
641 *Pollut* 2021; **270**: 116202.
- 642 43. Xu C, Yin S, Liu Y, et al. Prenatal exposure to chlorinated polyfluoroalkyl ether sulfonic acids and
643 perfluoroalkyl acids: Potential role of maternal determinants and associations with birth outcomes. *J*
644 *Hazard Mater* 2019; **380**: 120867.
- 645 44. Zheng P, Liu Y, An Q, et al. Prenatal and postnatal exposure to emerging and legacy per-
646 /polyfluoroalkyl substances: Levels and transfer in maternal serum, cord serum, and breast milk.
647 *Sci Total Environ* 2022; **812**: 152446.
- 648 45. Chen F, Yin S, Kelly BC, Liu W. Chlorinated Polyfluoroalkyl Ether Sulfonic Acids in Matched
649 Maternal, Cord, and Placenta Samples: A Study of Transplacental Transfer. *Environ Sci Technol*
650 2017; **51**(11): 6387-94.
- 651 46. Chen F, Yin S, Kelly BC, Liu W. Isomer-Specific Transplacental Transfer of Perfluoroalkyl Acids:
652 Results from a Survey of Paired Maternal, Cord Sera, and Placentas. *Environ Sci Technol* 2017;
653 **51**(10): 5756-63.
- 654 47. Liu YX, Li A, An Q, et al. Prenatal and postnatal transfer of perfluoroalkyl substances from mothers
655 to their offspring. *Crit Rev Env Sci Tec* 2022; **52**(14): 2510-37.
- 656 48. Liu Y, Li A, Buchanan S, Liu W. Exposure characteristics for congeners, isomers, and enantiomers
657 of perfluoroalkyl substances in mothers and infants. *Environ Int* 2020; **144**: 106012.

- 658 49. Liu Y, Zhou X, Wu Y, et al. Exposure and Blood–Cerebrospinal Fluid Barrier Permeability of PFASs
659 in Neonates. *Environ Sci Tech Let* 2021; **9**(1): 64-70.
- 660 50. Zhang LQ, Liu WW, Hou K, et al. Air pollution-induced missed abortion risk for pregnancies. *Nat*
661 *Sustain* 2019; **2**(11): 1011-7.
- 662 51. Xue T, Tong M, Li J, et al. Estimation of stillbirths attributable to ambient fine particles in 137
663 countries. *Nat Commun* 2022; **13**(1): 6950.
- 664 52. Fleischer NL, Meriardi M, van Donkelaar A, et al. Outdoor air pollution, preterm birth, and low birth
665 weight: analysis of the world health organization global survey on maternal and perinatal health.
666 *Environ Health Persp* 2014; **122**(4): 425-30.
- 667 53. Bai X, Ran J, Zhao X, Liang Y, Yang X, Xi Y. The S100A10-AnxA2 complex is associated with the
668 exocytosis of hepatitis B virus in intrauterine infection. *Lab Invest* 2022; **102**(1): 57-68.
- 669 54. Zhao P, Wen J, Qian L, Zhu X, Wang H, Bai X. Expression of S100 proteins is associated with HBV
670 intrauterine transmission. *Arch Gynecol Obstet* 2020; **302**(6): 1389-99.
- 671 55. Maier L, Goemans CV, Wirbel J, et al. Unravelling the collateral damage of antibiotics on gut
672 bacteria. *Nature* 2021; **599**(7883): 120-4.
- 673 56. Ji C, Zhang G, Xu S, et al. Antibiotic treatments to mothers during the perinatal period leaving
674 hidden trouble on infants. *Eur J Pediatr* 2022; **181**(9): 3459-71.
- 675 57. Chen H, Li H, Cao Y, et al. Food Intake and Diet Quality of Pregnant Women in China During the
676 COVID-19 Pandemic: A National Cross-Sectional Study. *Front Nutr* 2022; **9**: 853565.
- 677 58. Tu X, Chen R, Huang G, et al. Factors Predicting Severe Myelosuppression and Its Influence on
678 Fertility in Patients with Low-Risk Gestational Trophoblastic Neoplasia Receiving Single-Agent
679 Methotrexate Chemotherapy. *Cancer Manag Res* 2020; **12**: 4107-16.
- 680 59. Wen J, Bai XX. miR-520h Inhibits cell survival by targeting mTOR in gestational diabetes mellitus.
681 *Acta Biochim Pol* 2021; **68**(1): 65-70.
- 682 60. Shen J, Chen Q, Li N, Bai X, Wang F, Li B. TWIST1 expression and clinical significance in type I
683 endometrial cancer and premalignant lesions: A retrospective clinical study. *Medicine* 2020; **99**(48):
684 e23397.
- 685 61. Wen Y, Long Z, Bai X, Huo F, Yin C. Specific fluorescence release based on synergistic activation
686 of enzymes and position-dependent of electrophilic groups to diagnose intrahepatic cholestasis of
687 pregnancy. *J Chem Eng* 2022; **440**: 135978.
- 688